Axiom Advisory LLC Acquires 198 Shares of Moderna, Inc. (NASDAQ:MRNA)

Axiom Advisory LLC grew its holdings in Moderna, Inc. (NASDAQ:MRNA) by 1.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,672 shares of the company’s stock after purchasing an additional 198 shares during the period. Axiom Advisory LLC’s holdings in Moderna were worth $847,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Ashton Thomas Private Wealth LLC bought a new stake in Moderna during the 2nd quarter valued at $26,000. Family Firm Inc. bought a new stake in shares of Moderna during the 2nd quarter valued at $33,000. Cedar Wealth Management LLC lifted its holdings in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares in the last quarter. Westside Investment Management Inc. bought a new position in Moderna in the 1st quarter worth about $32,000. Finally, Bank & Trust Co purchased a new position in Moderna during the 2nd quarter valued at about $36,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Stock Down 0.6 %

MRNA opened at $58.39 on Wednesday. Moderna, Inc. has a 12 month low of $57.75 and a 12 month high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The business’s 50-day moving average price is $75.97 and its 200-day moving average price is $107.38. The company has a market cap of $22.38 billion, a P/E ratio of -3.73 and a beta of 1.66.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same period last year, the company earned ($3.62) EPS. Moderna’s revenue for the quarter was down 29.9% compared to the same quarter last year. On average, equities analysts expect that Moderna, Inc. will post -9.86 EPS for the current year.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 715 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Moderna news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, President Stephen Hoge sold 15,000 shares of the stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $121.12, for a total value of $1,816,800.00. Following the completion of the sale, the president now owns 1,442,089 shares of the company’s stock, valued at approximately $174,665,819.68. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 63,184 shares of company stock valued at $7,464,331 over the last three months. 15.70% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on MRNA. William Blair reissued a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. Bank of America cut their price target on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a report on Friday, September 13th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and decreased their price target for the stock from $85.00 to $80.00 in a report on Wednesday, August 7th. Barclays reduced their target price on Moderna from $155.00 to $125.00 and set an “overweight” rating for the company in a research report on Monday, September 16th. Finally, Oppenheimer lowered Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $100.44.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.